|Bid||304.02 x 800|
|Ask||313.89 x 800|
|Day's Range||309.66 - 320.00|
|52 Week Range||196.78 - 404.20|
|Beta (5Y Monthly)||0.89|
|PE Ratio (TTM)||66.23|
|Earnings Date||Oct 29, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||294.07|
If you own toxic stocks for a long period of time, you are sure to see huge erosion in your wealth. Figuring out such stocks and selling them at the right time is the key to successful investing.
The latter is a scrappy biotech stock that has found ways to survive, despite setbacks, for more than 25 years. Regardless of previous success, investing is about the future. DNA sequencer products, like Illumina's, allow scientists to determine the information and instructions carried by a DNA sample.
Although the masses and most of the financial media blame hedge funds for their exorbitant fee structure and disappointing performance, these investors have proved to have great stock picking abilities over the years (that’s why their assets under management continue to swell). We believe hedge fund sentiment should serve as a crucial tool of an […]
(Bloomberg) -- Exact Sciences Corp. said it will acquire Thrive Earlier Detection Corp. to gain technology for cancer screening in a deal worth as much as $2.15 billion.The cash and stock agreement will bring closely held Thrive’s CancerSeek technology to Exact Sciences, helping establish the Madison, Wisconsin-based company as a competitor in blood-based, multi-cancer screening, according to a statement. Exact Sciences jumped as much as 22% to $130, its highest since the shares began trading in 2001.Testing companies are increasingly developing liquid biopsies that sift through patients’ blood for early signs of tumors, hoping to help doctors begin treatment before the disease gets out of control. Exact Sciences’ acquisition marks the third such deal this year. Last month, Illumina Inc. snapped up Grail Inc. for roughly $8 billion ahead of its initial public offering while in June Invitae Corp. picked up another private company planning to go public, ArcherDx Inc., for about $1 billion.Exact Sciences’ deal is a “bargain” compared to Illumina’s, according to Vijay Kumar, an Evercore ISI analyst. The acquisition “removes the bear thesis that Exact Sciences could be cannibalized by liquid biopsy tests,” he wrote in a research note. The market for a simple blood test that can detect cancers is enormous, with some analyst estimates putting it at $30 billion or more.CancerSeek looks for gene mutations and other markers that can potentially help spot several forms of cancer. The merger will lead to improvements in the accuracy of CancerSeek and get the test in front of doctors and patients faster, Exact Sciences Chief Executive Kevin Conroy said in a phone interview.Conroy and Thrive expect to start a large registrational study likely including tens of thousands of patients next year. The trial will target multiple different cancer types and the effort will likely take years “to do the right way,” Conroy said.The pursuit of a viable cancer detection test is a crowded one. Also racing alongside Exact Sciences, Illumina and Invitae are Guardant Health Inc. and closely-held Freenome Inc. “Cancer is the number two cause of death in the U.S.,” Conroy said. “There will be multiple tests.”Exact Sciences was an early backer of Thrive.Under the terms of the agreement, Thrive will receive $1.7 billion at the deal’s closing, with 65% in Exact Sciences common stock and 35% in cash, subject to certain adjustments. Thrive would receive an additional $450 million based on reaching goals in developing its testing technology. The deal is expected to close in the first quarter of 2021.Exact Sciences also announced a deal for Base Genomics Ltd. for $410 million to expand its testing technology.(Adds CEO Conroy’s comments from fifth paragraph on)For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2020 Bloomberg L.P.
Bonsai Partners recently released its Q3 2020 Investor Letter, a copy of which you can download here. The fund posted a return of 63.3% for the quarter (net of fees), outperforming their benchmark, the S&P 500 Index which returned 8.9% in the same quarter. You should check out Bonsai Partners’ top 5 stock picks for […]
ARK Investment’s Cathie Wood is a student of disruption innovation. Why she thinks Tesla will leave ride-hailing leaders Uber and Lyft in a cloud of dust.
Illumina (ILMN) is upbeat about its third-quarter sequencing consumable revenue growth.
Illumina (ILMN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
It's easy to underappreciate just how much progress has been made in researching SARS-CoV-2, the novel coronavirus that causes COVID-19. During the last major pandemic to hit the U.S. (the 1918 influenza pandemic), scientists didn't even conclusively determine that a virus -- instead of a bacterium -- caused the deadly flu until 1930, more than a decade after the end of the pandemic. Earlier this year, the genomic sequence for SARS-CoV-2 was mapped.
|Downgrade||Guggenheim: Buy to Neutral||10/13/2020|
|Initiated||Atlantic Equities: to Overweight||9/30/2020|
|Maintains||Canaccord Genuity: to Hold||9/22/2020|
|Maintains||Baird: to Neutral||9/22/2020|
|Downgrade||UBS: Buy to Neutral||9/22/2020|
|Downgrade||Stifel: Buy to Hold||9/22/2020|
Industry: Diagnostics & Research
Full Time Employees: 7,700
Illumina, Inc. provides sequencing and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets enabling the adoption of genomic solutions in research and clinical settings for applications in the life sciences, oncology, reproductive health, agriculture and other emerging segments. The company provides instruments and consumables used in genetic analysis; and genotyping and sequencing services, instrument service contracts, and development and licensing agreements. Its customers include genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers in North America, Europe, Latin America, and the Asia-Pacific region, as well as sells through life-science distributors in certain markets within Europe, the Asia-Pacific region, Latin America, the Middle East, and Africa. Illumina, Inc. was founded in 1998 and is headquartered in San Diego, California.